In contrast, EGCG in conjunction with irinotecan has been shown to suppress the production of ROS in colorectal cancer, where the altered redox homeostasis, along with the regulation of GRP78, collectively enhances the chemosensitivity of colorectal cancer cells to irinotecan [190]. This evidence concerns the gene HSPA5 and colorectal cancer.